Antifungal Drugs Market by Drug Type - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4333224
  • Report
  • Region: Global
  • 190 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer Ag
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc.
  • Merck & Co., Inc.
  • Novartis International Ag
  • MORE
Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others) Some of the common fungal infections such as athlete’s foot, fungal meningitis, ringworm and other infections can be treated by antifungal drugs that work by killing of the fungal cell breaking the contents of the cell. These cells eventually leak out and results in the death of the cell, which also prevents the cell to grow further, thus preventing the infection. The global antifungal drugs market was valued at $13,719 million in 2016, and is expected to reach at $17,718 million by 2023, registering a CAGR of 3.7% from 2017 to 2023.

There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.

The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
Key market players and their strategies are provided to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Type

Echinocandins
Caspofungin
Micafungin
Anidulafungin
Others
Azoles
Imidazoles
Voriconazole
Thiazoles
Others
Polyenes
Amphotericin B
Candicidin
Hamycin
Natamycin
Others
Allylamines
Butenafine
Terbinafine
Naftifine
Others

By Infection Type

Superficial Antifungal Infections
Systemic Antifungal Infections
By Therapeutic Indications

Aspergillosis
Dermatophytosis
Candidiasis
Others

By Dosage Forms

Powders
Ointments
Drugs
Others

By Geography

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Spain
Rest of Europe
Asia-pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Egypt
Israel
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED

Pfizer Inc.
Sanofi S.A.
Gilead Sciences, Inc.
Merck & Co., Inc.
Scynexis Inc.
Novartis International AG
Abbott Laboratories
Bayer AG
Enzon Pharmaceuticals, Inc.
GlaxoSmithKline Plc.

The other players in the value chain include (profiles not included in the report)

Sigma-Aldrich Corporation
Agilent Technologies, Inc.
Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
Tecan Group
Astellas Pharma, Inc.
Basilea Pharmaceutical Ltd.
Valeant Pharmaceuticals International, Inc.
Kramer Laboratories
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer Ag
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc.
  • Merck & Co., Inc.
  • Novartis International Ag
  • MORE
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases

3.6.2. Restraints

3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs

3.6.3. Opportunities

3.6.3.1. Patent expirations and increasing funding from public & private organizations

CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SUPERFICIAL ANTIFUNGAL INFECTION

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SYSTEMIC ANTIFUNGAL INFECTION

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ECHINOCANDINS

5.2.1. Market size and forecast
5.2.2. Micafungin

5.2.2.1. Market size and forecast

5.2.3. Caspofungin

5.2.3.1. Market size and forecast

5.2.4. Anidulafungin

5.2.4.1. Market size and forecast

5.2.5. Others

5.2.5.1. Market size and forecast

5.3. AZOLES

5.3.1. Market size and forecast
5.3.1. Imidazoles

5.3.1.1. Market size and forecast

5.3.2. Voricanazole

5.3.2.1. Market size and forecast

5.3.3. Thiazoles

5.3.3.1. Market size and forecast

5.3.4. Others

5.3.4.1. Market size and forecast

5.4. POLYENES

5.4.1. Market size and forecast
5.4.2. Amphotericin B

5.4.2.1. Market size and forecast

5.4.3. Candicidin

5.4.3.1. Market size and forecast

5.4.4. Hamycin

5.4.4.1. Market size and forecast

5.4.5. Natamycin

5.4.5.1. Market size and forecast

5.4.6. Others

5.4.6.1. Market size and forecast

5.5. ALLYLAMINES

5.5.1. Market size and forecast
5.5.1. Terbinafine

5.5.1.1. Market size and forecast

5.5.2. Butenafine

5.5.2.1. Market size and forecast

5.5.3. Naftifine

5.5.3.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ASPERGILLOSIS

6.2.1. Market size and forecast

6.3. DERMATOPHYTOSIS

6.3.1. Market size and forecast

6.4. CANDIDIASIS

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. POWDER

7.2.1. Market size and forecast

7.3. OINTMENTS

7.3.1. Market size and forecast

7.4. DRUGS

7.4.1. Market size and forecast

7.5. OTHERS

7.5.1. Market size and forecast

CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. PFIZER INC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. SANOFI S.A

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. GILEAD SCIENCES INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. MERCK & CO., INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. NOVARTIS INTERNATIONAL AG

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. ABBOTT LABORATORIES

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. BAYER AG

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. SCYNEXIS INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. ENZON PHARMACEUTICALS INC.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. GLAXOSMITHKLINE PLC

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer Ag
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc.
  • Merck & Co., Inc.
  • Novartis International Ag
  • MORE
According to a new report titled, Antifungal Drugs Market by Drug type, Infection type, Indication, and Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global antifungal drugs market was valued at $13,719 million in 2016, and is projected to reach $17,718 million by 2023, growing at a CAGR of 3.7% from 2017 to 2023. The azoles drug segment accounted for nearly three-eighths share of the total market in 2016.

Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.
The growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad fungal infections, and increase in demands of generic drugs are the major factors that drive the market growth. However, patent expiration of branded therapeutics and presence of counterfeit drugs restrain the growth of the antifungal drugs market. In addition, increase in R&D expenditure coupled with funding from the public & private sector is expected to provide lucrative growth opportunities to the antifungal drugs market.
The systemic antifungals segment is anticipated to maintain its dominance during the forecast period, accounting for about fifth-sevenths share of the global antifungal drugs market in 2016. This is due to the high usage of drugs such as azole for all the fungal indications and these also offer broad spectrum activity and improved safety levels. In addition, rise in prevalence of most commonly occurring systematic fungal infection such as candidiasis supplements the market growth. However, the superficial antifungals are expected to grow rapidly throughout the forecast period. This is because of the growth in incidence of hospital-acquired infections and increase in life expectancy among people.
The dermatophytosis indication is expected to register the highest CAGR of 4.1% throughout the forecast period. This is because of high incidences of skin infections in both children and adults. Candidiasis indication generated the highest revenue in 2016, accounting for about one-third of the total share in 2016, and is anticipated to maintain this trend from 2017 to 2023.

Key Findings of the Antifungal Drugs Market:
The superficial antifungals are anticipated to grow at a highest rate during the analysis period.
The U.S. was the major shareholder in the North America antifungal drugs market, and accounted for the highest share in 2016.
The antifungal drugs occupied about two-sevenths share of the total antifungal drugs market by dosage form in 2016 and is expected to retain its dominant share throughout the forecast period.
China occupied one-fifth share of the total Asia-Pacific antifungal drugs market in 2016, registering a CAGR of 4.8% from 2017 to 2023.
The azole drug type dominated the market in 2016, growing at a CAGR of 3.9% from 2017 to 2023.
In 2016, Asia-Pacific and LAMEA collectively accounted for about three-eighths share of the market and is expected to continue this trend throughout the forecast period. Increase in awareness regarding antifungal drugs, availability of these drugs specifically in China, India, and the other developing economies, and growth in awareness regarding the fungal diseases drive the market. Moreover, the massive target population and growth in economy catering to the establishment of healthcare facilities boost the market.
The report provides a comprehensive analysis of the key players operating in the global antifungal drugs market such as Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc.
The other players of the global antifungals drugs market include Astellas Pharma, Inc., Sigma-Aldrich Corporation, Agilent Technologies, Inc., Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Kramer Laboratories, Basilea Pharmaceutical Ltd., Valeant Pharmaceuticals International, Inc., and Tecan Group.
Note: Product cover images may vary from those shown
5 of 5
  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Scynexis Inc.
  • Novartis International Ag
  • Abbott Laboratories
  • Bayer Ag
  • Enzon Pharmaceuticals, Inc.
  • Glaxosmithkline Plc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll